Patents by Inventor Yves Lobet
Yves Lobet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9655958Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.Type: GrantFiled: January 23, 2015Date of Patent: May 23, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Rhea Coler, Steven Reed, Yves Lobet, Martine Marchand
-
Publication number: 20170065696Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.Type: ApplicationFiled: January 23, 2015Publication date: March 9, 2017Applicant: GLAXOSMITHKILINE BIOLOGICALS S.A.Inventors: Rhea COLER, Steven REED, Yves LOBET
-
Publication number: 20160175423Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are characterized by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.Type: ApplicationFiled: March 2, 2016Publication date: June 23, 2016Inventors: Francois-Xavier Jacques BERTHET, Wilfried LJ DALEMANS, Philippe DENOEL, Joelle THONNARD, Christiane FERON, Jan POOLMAN, Georges THIRY, Pierre VOET, Yves LOBET, Guy DEQUESNE
-
Publication number: 20150231224Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.Type: ApplicationFiled: January 23, 2015Publication date: August 20, 2015Applicant: GLAXOSMITHKILINE BIOLOGICALS S.A.Inventors: Rhea COLER, Steven REED, Yves LOBET
-
Patent number: 9056913Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.Type: GrantFiled: May 16, 2013Date of Patent: June 16, 2015Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Rhea Coler, Yves Lobet, Steven Reed
-
Publication number: 20140294935Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.Type: ApplicationFiled: May 12, 2014Publication date: October 2, 2014Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, George Thiry, Joelle Thonnard, Pierre Voet
-
Publication number: 20140099339Abstract: The present invention relates to a combination of 2 or more S pneumoniae proteins, their manufacture and use in medicine as a vaccine. Such combinations are particularly useful for the protection of infants and elderly against streptococcal infection.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe Hermand, Craig A. J. Laferriere, Yves Lobet, Jan Poolman
-
Publication number: 20140050776Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.Type: ApplicationFiled: May 16, 2013Publication date: February 20, 2014Applicants: INFECTIOUS DISEASE RESEARCH INSTITUTE, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Rhea COLLER, Yves Lobet, Steven Reed
-
Patent number: 8541007Abstract: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.Type: GrantFiled: December 21, 2010Date of Patent: September 24, 2013Assignees: GlaxoSmithKline Biologicals S.A., Corixa CorporationInventors: Mark Alderson, Ajay Bhatia, Yves Lobet, Brenda Maisonneuve, Jean-Francois L Maisonneuve, Martine Marchand, Pascal Mettens, Florence Bernadette Nozay, Peter Probst, Samira H Skeiky
-
Patent number: 8470338Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.Type: GrantFiled: April 27, 2006Date of Patent: June 25, 2013Assignees: GlaxoSmithKline Biologicals, S.A., Infectious Disease Research InstituteInventors: Rhea Coler, Yves Lobet, Steven Reed
-
Publication number: 20110300206Abstract: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.Type: ApplicationFiled: December 21, 2010Publication date: December 8, 2011Applicants: GlaxoSmithKline Biologicals, sa, Corixa CorporationInventors: Mark ALDERSON, Ajay BHATIA, Yves LOBET, Brenda MAISONNEUVE, Jean-Francois L. MAISONNEUVE, Martine MARCHAND, Pascal METTENS, Florence Bernadette NOZAY, Peter PROBST, Yasir A. SKEIKY, Samira H. SKEIKY
-
Publication number: 20100172927Abstract: Methods and compositions for the treatment or prevention of ocular Chlamydia trachomatis infection. Compositions comprise one or more Chlamydia trachomatis proteins, immunogenic fragments thereof or polynucleotides encoding such proteins or fragments.Type: ApplicationFiled: October 3, 2007Publication date: July 8, 2010Inventors: Mark Alderson, Rhea Coler, Yves Lobet, Jean-Francois L. Maisonneuve, Pascal Mettens, Peter Probst, Steven Reed
-
Publication number: 20090191234Abstract: This invention relates to three newly-identified, distinct groups of antigenic peptides [LB1(f) peptides] from the same region of the P5-like fimbrin protein discovered using sequence data from the fimbrin protein of many Haemophilus influenzae strains. The invention additionally provides chimeric polypeptides that carry one or more representatives of such peptides from different groups and which induce an immunogenic response in animals to Haemophilus influenzae. The peptides and polypeptides of the invention will be useful in vaccine compositions which provide protection against a wide range of H. influenzae strains.Type: ApplicationFiled: December 23, 2008Publication date: July 30, 2009Applicants: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION, SMITHKLINE BEECHAM BIOLOGICALS S.A.Inventors: Lauren Bakaletz, Joseph Cohen, Guy Dequesne, Yves Lobet
-
Publication number: 20090123491Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.Type: ApplicationFiled: April 27, 2006Publication date: May 14, 2009Inventors: Rhea Coler, Yves Lobet, Steven Reed
-
Publication number: 20090117147Abstract: The present invention relates to the field of vaccine formulation, particularly the field of novel adjuvant compositions comprising outer membrane vesicles (or blebs), and advantageous methods of detoxifying these compositions, and advantageous methods of use of such adjuvants.Type: ApplicationFiled: December 3, 2007Publication date: May 7, 2009Inventors: Francois-Xavier Jacques BERTHET, Wilfried L J. Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Nathalie Garcon, Yves Lobet, Jan Poolman, Georges Thiry, Joelle Thonnard, Pierre Voet
-
Publication number: 20090022755Abstract: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.Type: ApplicationFiled: March 24, 2006Publication date: January 22, 2009Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, CORIXA CORPORATIONInventors: Brenda Barth, Ajay Bhatia, Mark Alderson, Jean-Francois L. Maisonneuve, Yves Lobet, Florence Bernadette Nozay, Martine Marchand, Pascal Mettens, Yasir A. Skeiky, Peter Probst
-
Publication number: 20080233154Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.Type: ApplicationFiled: August 25, 2006Publication date: September 25, 2008Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, Georges Thiry, Joelle Thonnard, Pierre Voet
-
Publication number: 20080081050Abstract: The present invention relates to a combination of 2 or more S pneumoniae proteins, their manufacture and use in medicine as a vaccine. Such combinations are particularly useful for the protection of infants and elderly against streptococcal infection.Type: ApplicationFiled: May 7, 2007Publication date: April 3, 2008Inventors: Philippe Hermand, Craig Laferriere, Yves Lobet, Jan Poolman
-
Publication number: 20060257418Abstract: This invention relates to three newly-identified, distinct groups of antigenic peptides [LB1(f) peptides] from the same region of the P5-like fimbrin protein discovered using sequence data from the fimbrin protein of many Haemophilus influenzae strains. The invention additionally provides chimeric polypeptides that carry one or more representatives of such peptides from different groups and which induce an immunogenic response in animals to Haemophilus influenzae. The peptides and polypeptides of the invention will be useful in vaccine compositions which provide protection against a wide range of H. influenzae strains.Type: ApplicationFiled: January 23, 2006Publication date: November 16, 2006Inventors: Lauren Bakaletz, Joseph Cohen, Guy Dequesne, Yves Lobet
-
Publication number: 20060216307Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.Type: ApplicationFiled: June 9, 2006Publication date: September 28, 2006Inventors: Francois-Xavier Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, Georges Thiry, Joelle Thonnard, Pierre Voet